Sökning: WFRF:(Popov Todor A.)
> (2013) >
Effect of monteluka...
Effect of montelukast for treatment of asthma in cigarette smokers
-
Price, David (författare)
-
Popov, Todor A. (författare)
-
- Bjermer, Leif (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
visa fler...
-
Lu, Susan (författare)
-
Petrovic, Romana (författare)
-
Vandormael, Kristel (författare)
-
Mehta, Anish (författare)
-
Strus, Jolanta D. (författare)
-
Polos, Peter G. (författare)
-
Philip, George (författare)
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2013
- 2013
- Engelska.
-
Ingår i: Journal of Allergy and Clinical Immunology. - : Elsevier BV. - 1097-6825 .- 0091-6749. ; 131:3, s. 763-771
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Many asthmatic patients are unable to quit cigarettes; therefore information is needed on treatment options for smokers. This study evaluates 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily, each compared with placebo, in patients with self-reported active smoking (unable to quit) and asthma. Methods: Patients (ages 18-55 years, with asthma [>= 1 year], FEV1 of 60% to 90% of predicted value, airway reversibility [>= 12%], and self-reported active smoking [>= 0.5 to <= 2 packs per day]) were randomized (after a 3-week, single-blind, placebo, run-in period) to 1 of 3 parallel, 6-month, double-blind treatment arms. The primary efficacy end point was the percentage of days with asthma control during treatment. Adverse experiences (AEs) were also evaluated. Results: There were 347, 336, and 336 patients randomized to montelukast, fluticasone, and placebo, respectively. The mean percentage of days with asthma control over 6 months of treatment was 45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); the difference between montelukast and fluticasone was not significant (P = .14). Patients with a smoking history of <= 11 pack years (the median value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11 pack years tended to show more benefit with montelukast. AEs occurred in similar proportions among treatment groups. Conclusions: In a population of asthmatic patients actively smoking cigarettes, both 10 mg/d montelukast and 250 mu g of fluticasone propionate twice daily significantly increased the mean percentage of days with asthma control compared with placebo. (J Allergy Clin Immunol 2013;131:763-71.)
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- Montelukast
- smoking
- fluticasone propionate
- leukotriene receptor
- antagonist
- asthma control
- corticosteroids
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Price, David
-
Popov, Todor A.
-
Bjermer, Leif
-
Lu, Susan
-
Petrovic, Romana
-
Vandormael, Kris ...
-
visa fler...
-
Mehta, Anish
-
Strus, Jolanta D ...
-
Polos, Peter G.
-
Philip, George
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Lungmedicin och ...
- Artiklar i publikationen
-
Journal of Aller ...
- Av lärosätet
-
Lunds universitet